OnCore Login

Return to Trial Database

BRE12-158

A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients with Triple Negative Breast Cancer.

Status

Study Completed

Cancer Type(s)

Breast

Study Contact

Publications

Circulating TP53 mutations in TNBC after neoadjuvant chemotherapy is associated with rapid disease recurrence: Correlative analysis from clinical trial BRE12-158
  • M Radovich, N Kassem, G Jiang, BA Hancock, BP Schneider
Detection of circulating tumor DNA (ctDNA) after neoadjuvant chemotherapy is significantly associated with disease recurrence in early-stage triple-negative breast cancer (TNBC): Preplanned correlative results from clinical trial BRE12-158
  • M Radovich, G Jiang, C Chitambar, R Nanda, C Falkson, FC Lynce, C Gallagher, C Isaacs, M Blaya, E Paplomata, R Walling, K Daily, R Mahtani, MA Thompson, R Graham, ME Cooper, DC Pavlick, L Albacker, J Gregg, CL Bales, BA. Hancock, E Cantor, F Shen, AMV Storniolo, S Badve, T Ballinger, KD Miller, BP Schneider
A phase II randomized controlled trial of genomically directed therapy after preoperative chemotherapy in patients with triple negative breast cancer (TNBC)
  • B Schneider, KD Miller, S Badve, B O'Neil, P Helft, C Chitambar, C Falkson, R Nanda, M McCormick, M Danso, M Blaya, R Langdon, M Lippman, E Paplomata, R Walling, M Thompson, E Robin, L Aggarwal, I Shalaby, V Canfield, B Adesunloye, T Lee, K Daily, C Ma, J Erban, N Radhakrishnan, D Bruetman, M Graham, NA Reddy, FC Lynce, M Radovich
BRE12-158: A Post-neoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician’s Choice for Patients with Residual Triple-Negative Breast Cancer
  • BP Schneider, G Jiang, MS, TJ Ballinger, F Shen, C Chitambar, R Nanda, C Falkson, MBBch, FC Lynce , C Gallagher, C Isaacs, M Blaya, E Paplomata, R Walling, K Daily, R Mahtani, MA Thompson, R Graham, ME Cooper, DC Pavlick , LA Albacker, J Gregg, JP Solzak, YH Chen, CL Bales, E Cantor, BA Hancock, N Kassem, P Helft, B O'Neil, AMV Storniolo, S Badve, KD Miller, M Radovich
Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial
  • M Radovich, G Jiang, BA Hancock, C Chitambar, R Nanda, C Falkson, FC Lynce, C Gallagher, C Isaacs, M Blaya, E Paplomata, R Walling, K Daily, R Mahtani, MA Thompson, R Graham, ME Cooper, DC Pavlick, LA Albacker, J Gregg, JP Solzak, Y Chen, CL Bales, E Cantor, F Shen, AMV Storniolo, S Badve, TJ Ballinger, C Chang, Y Zhong, C Savran, KD Miller, BP Schneider
A phase II randomized controlled trial of genomically directed therapy after preoperative chemotherapy in patients with triple negative breast cancer (TNBC). A phase II randomized controlled trial of genomically directed therapy after preoperative chemotherapy in patients with triple negative breast cancer
  • B Schneider, KD Miller, S Badve, B O'Neil, P Helft, C Chitambar, C Falkson, R Nanda, M McCormick, M Danso, M Blaya, R Langdon, M Lippman, E Paplomata, R Walling, M Thompson, E Robin, L Aggarwal, I Shalaby, V Canfield, B Adesunloye, T Lee, K Daily, C Ma, J Erban, N Radhakrishnan, D Bruetman, M Graham, NA Reddy, FC Lynce, M Radovich

Trial Locations

All sites in which the trial BRE12-158 being conducted in.
No data was found
  • 7676 Interactive Way, Suite 120, Indianapolis, IN 46278